Selection and Initiation of Long‑Acting Basal Insulin

Preferred Basal Insulin Class

• The American Association of Clinical Endocrinology (AACE) 2023 guidelines recommend analog insulins (detemir, glargine, degludec) over human NPH insulin to lower rates of symptomatic and nocturnal hypoglycemia. 1, 2, 3

First‑ vs. Second‑Generation Analogs

• First‑generation analogs (glargine U100, detemir) reduce hypoglycemia compared with NPH insulin. 4, 5
• Second‑generation analogs (glargine U300, degludec U100/U200) provide greater pharmacologic stability and further lower nocturnal hypoglycemia risk versus glargine U100. 2, 3, 4
• Because of their longer time to steady state, second‑generation formulations require slower titration (≥ 3 days between dose adjustments). 1, 2, 3

Initiation in Typical Patients

• For most adults starting basal insulin, any of the analog insulins—detemir, glargine U100, glargine U300, or degludec—are appropriate first‑choice options. 1, 2, 3
• In patients at higher hypoglycemia risk (e.g., older adults, those with renal impairment, or hypoglycemia unawareness), glargine U300 or degludec is preferred. 4

High‑Dose and Concentrated Formulations

• When daily insulin requirements exceed 0.5 units/kg or 200 units, concentrated formulations (glargine U300 or degludec U200) allow delivery of larger doses in a smaller injection volume. 6, 7

Hospital (Non‑Critical Care) Use

• In non‑critical care inpatient settings, once‑daily or twice‑daily glargine or detemir is recommended over NPH insulin. 8, 9, 10
• If needed, detemir or NPH may be administered twice daily to achieve glycemic targets. 8, 10

Initial Dose Calculation

• A1C < 8 % – start at 0.1–0.2 units/kg/day. 2
• A1C ≥ 8 % – start at 0.2–0.3 units/kg/day. 2
• An alternative fixed starting dose of 10 units daily may be used regardless of body weight when simplicity is required. 6, 7

Titration Schedule

• Standard analogs (glargine U100, detemir, NPH) are titrated every 2–3 days. 3
• Longer‑acting analogs (glargine U300, degludec) are titrated every 3–5 days because of their extended half‑life. 2, 3, 4

Titration Adjustments Based on Fasting Glucose

*All adjustments follow AACE 2023 guidance. 1

Switching Between Basal Formulations

• Basal insulins can generally be converted unit‑for‑unit, with subsequent dose fine‑tuning based on glucose monitoring. 4
• When switching from detemir or glargine U300 to another basal insulin in patients with tight control or high hypoglycemia risk, reduce the initial dose by 10–20 %. 4

Avoiding Over‑Basalization

• Do not increase basal insulin beyond 0.5–1.0 units/kg/day without a meaningful reduction in fasting glucose. 4, 5
• Indicators of over‑basalization include:
  
  • Bedtime‑to‑morning glucose differential ≥ 50 mg/dL,
  • Occurrence of hypoglycemia (aware or unaware),
  • High glucose variability. 4, 5
• When over‑basalization is identified, consider adding prandial insulin or a GLP‑1 receptor agonist rather than further increasing basal insulin. 4, 5

Concomitant Oral Medications

• After basal insulin initiation, discontinue sulfonylureas to lower hypoglycemia risk. 1, 2, 3
• Continue metformin; the combination with basal insulin attenuates weight gain and reduces insulin dose requirements. 8, 5

Cost Considerations

• NPH insulin remains an acceptable, lower‑cost alternative when budget constraints preclude analog use, but it carries a higher hypoglycemia risk. 6, 7, 5

Basal Insulin Initiation Recommendations

Preferred Basal Insulin Analogs

• The American Association of Clinical Endocrinology recommends initiating basal insulin with a long‑acting analog (insulin glargine U‑100 or U‑300, insulin degludec U‑100 or U‑200, or insulin detemir), noting that second‑generation analogs (glargine U‑300 and degludec) provide the lowest risk of hypoglycemia. 11
• AACE explicitly advises using analog insulins (detemir, glargine, or degludec) instead of NPH insulin because they markedly lower both nocturnal and overall hypoglycemia while achieving comparable or superior glycemic control. 11
• AACE states that NPH insulin may be considered only when cost prohibits analog use, given its substantially higher hypoglycemia risk and requirement for twice‑daily dosing. 11

Initial Dosing Based on Glycemic Status

• For adults with baseline A1C < 8 %, AACE recommends starting basal insulin at 0.1–0.2 units/kg/day. 11
• For adults with baseline A1C ≥ 8 %, AACE recommends starting basal insulin at 0.2–0.3 units/kg/day. 11

Titration Strategies

• With standard long‑acting analogs (glargine U‑100, detemir), AACE advises titrating the dose every 2–3 days based on fasting glucose measurements. 11
• With longer‑acting analogs (glargine U‑300, degludec), AACE advises titrating more slowly, every 3–5 days, due to their extended time to steady‑state. 11
• AACE sets the target fasting blood glucose to < 110 mg/dL without inducing hypoglycemia. 11

Concomitant Medication Management

• AACE recommends discontinuing sulfonylureas immediately when basal insulin is initiated to avoid additive hypoglycemia risk. 11
• AACE supports adding or continuing a GLP‑1 receptor agonist with basal insulin to achieve greater A1C reduction, promote weight loss, and lower hypoglycemia rates compared with insulin alone. 11

Patient Education and Self‑Management

• AACE emphasizes patient education on self‑monitoring fasting glucose and providing a written self‑titration algorithm, which significantly improves glycemic outcomes. 11
• AACE advises teaching patients to recognize hypoglycemia (glucose < 70 mg/dL), treat it with 15 g of fast‑acting carbohydrate, and apply dose‑reduction protocols. 11

Basal Insulin Initiation and Management in Adults

Initial Dosing Based on Weight and Glycemic Control

• The American Association of Clinical Endocrinology (AACE) recommends a starting basal insulin dose of 0.1–0.2 U/kg/day (≈ 7–14 U for a 70‑kg adult) when baseline A1C is < 8 %, and 0.2–0.3 U/kg/day (≈ 14–21 U) when baseline A1C is ≥ 8 %, using a long‑acting analog such as glargine or degludec. [12][13]

Preferred Basal Insulin Formulations

• AACE strongly recommends long‑acting basal analogs (glargine U‑100/U‑300, degludec U‑100/U‑200, detemir) over NPH insulin because they reduce nocturnal and overall hypoglycemia by 20–40 % while providing equivalent or superior glycemic control. 12

Titration Strategies

Standard Analogs (Glargine U‑100, Detemir)

• Titrate every 2–3 days based on fasting glucose values.

[[12][13]]

Longer‑Acting Analogs (Glargine U‑300, Degludec)

• Titrate every 3–5 days because these formulations require a longer period to reach steady‑state. [12][13]

Fixed‑Dose Simplified Approach

• Increase the basal dose by 2 U every 3 days until fasting glucose targets are achieved. 12

Glycemic Targets

• Aim for a fasting glucose < 110 mg/dL without hypoglycemia. [12][13]
• For older adults or patients with significant comorbidities, a more relaxed target of 90–150 mg/dL is appropriate. [14][15]16

Risks of Over‑Basalization

• Do not exceed 0.5–1.0 U/kg/day (≈ 35–70 U for a 70‑kg adult) without a meaningful reduction in fasting glucose. 12
• Clinical signs of over‑basalization include:
• When over‑basalization occurs, add prandial insulin or a GLP‑1 receptor agonist rather than further increasing basal insulin. 12

Special Populations

• Severe symptomatic hyperglycemia (A1C > 10 % or glucose ≥ 300 mg/dL with weight loss): start both basal and prandial insulin simultaneously, using the weight‑based basal dose plus 5 U or 10 % of the basal dose of rapid‑acting insulin before the largest meal. [12][13]

Patient Education

• Provide patients with a written self‑titration algorithm to guide dose adjustments. 13

Starting and Titrating Basal Insulin in Adults with Type 2 Diabetes

Weight‑Based Starting Doses

• The American College of Endocrinology and the American Association of Clinical Endocrinologists recommend initiating basal insulin at 0.1–0.2 U/kg/day when A1C < 8 % and at 0.2–0.3 U/kg/day when A1C ≥ 8 % for most adults with type 2 diabetes【17】【18】【19】.

Dose Reductions for High‑Risk Populations

• In patients ≥ 70 years old, with eGFR < 60 mL/min, or at high risk for hypoglycemia, the starting dose should be reduced to 0.1–0.2 U/kg/day regardless of A1C【20】.

Simplified Fixed‑Dose Option

• When weight‑based calculation is impractical, an initial dose of 10 U once daily is acceptable for any patient【21】.

Management of Severe Hyperglycemia with Symptoms

• For patients with A1C > 10 % or blood glucose ≥ 300 mg/dL plus symptomatic hyperglycemia, start basal insulin at 0.2–0.3 U/kg/day【17】【18】【19】.
• Add a single prandial insulin dose before the largest meal at 5 U or ≈ 10 % of the basal dose【17】【18】【19】.
• GLP‑1 receptor agonists should not be used alone in this acute setting because they require titration and delay glucose control【17】【19】.
• Testing for autoimmune (type 1) diabetes should be considered in these patients【17】【19】.

Titration Strategies

Standard Titration for First‑Generation Analogs

• Adjust the basal dose every 2–3 days for glargine U100, detemir, or NPH insulin【17】【21】.

Slower Titration for Second‑Generation Analogs

• For glargine U300 or degludec U100/U200, titrate every 3–5 days because steady‑state is reached more slowly【17】【21】【19】.

Simplified Fixed‑Increment Method

• Increase the dose by 2 U every 3 days until the fasting glucose target is achieved【17】【21】.

Target Fasting Glucose

• Aim for < 110 mg/dL without hypoglycemia for most patients【17】【19】.
• An alternative acceptable range is 90–130 mg/dL【21】.

Avoiding Over‑Basalization

Upper Limit of Basal Dose

• Do not increase basal insulin beyond 0.5–1.0 U/kg/day unless there is a meaningful reduction in fasting glucose【19】.

Clinical Indicators of Over‑Basalization

• Bedtime‑to‑morning glucose differential ≥ 50 mg/dL【17】【19】.
• Persistent hypoglycemia (aware or unaware)【17】【19】.
• High glucose variability despite high basal doses【17】【19】.

Management When Over‑Basalization Occurs

• Add prandial insulin before meals rather than further increasing basal insulin【17】【19】.
• Add a GLP‑1 receptor agonist to improve post‑prandial control and reduce total insulin requirements【21】【19】.
• Consider switching to a fixed‑ratio combination of basal insulin and GLP‑1 RA (e.g., iGlarLixi or IDegLira)【21】.

Preferred Basal Insulin Formulations

• Long‑acting analogs (glargine, degludec, detemir) are preferred over NPH because they provide equivalent or superior glycemic control with 20–40 % lower nocturnal and overall hypoglycemia (expert consensus).

Concomitant Medication Management

Discontinuation at Insulin Initiation (Hospitalized Patients)

• Other oral diabetes medications should be stopped when basal insulin is started in the hospital setting【20】.

Continuation or Addition

• Adding or continuing a GLP‑1 receptor agonist with basal insulin yields greater A1C reduction, weight loss, and lower hypoglycemia rates compared with insulin alone【21】.

Insulin Initiation in Hospitalized Non‑Critical Patients

• For in‑patients who are eating and have BG > 140 mg/dL, start basal insulin at 0.2–0.3 U/kg/day【20】.
• Reduce to 0.2 U/kg/day in patients ≥ 70 years or with eGFR < 60 mL/min【20】.
• Increase to 0.4 U/kg/day when BG is 140–200 mg/dL【20】.
• Increase to 0.5 U/kg/day when BG is 201–400 mg/dL【20】.

• Distribute the total daily dose as 50 % basal insulin and 50 % nutritional (prandial) insulin【20】.

• For patients who are NPO, give basal insulin alone with correction doses of a rapid‑acting analog every 4 hours (or regular insulin every 6 hours)【20】.

Common Pitfalls to Avoid

• Do not rely solely on sliding‑scale correction insulin without scheduled basal insulin; this reactive approach leads to poor control and worse outcomes【20】.
• Do not target only morning fasting glucose when titrating basal insulin; monitor afternoon and evening glucose to avoid over‑basalization【17】【19】.